Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology
Bio-Techne (NASDAQ: TECH) has launched an expanded menu of RNAscope™ in situ hybridization probes for human and mouse transcriptome research. This expansion aims to advance spatial biology research and the development of next-generation therapeutics and diagnostics. The Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across more than 450 species. RNAscope is noted for its spatial precision, sensitivity, and specificity, providing a single-cell view of disease pathology and therapeutic response.
This expansion allows customers to accelerate the validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available on bio-techne.com, customers can easily select RNAscope probes along with R&D Systems antibodies to study changes in cell phenotypes and functional states. The probes come in manual and automated formats, including compatibility with the Lunaphore COMET™ system, enabling seamless advancement from late discovery to translational research or clinical assay development.
Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, emphasized that the expanded portfolio, with over 12,000 citations in clinical and translational research, empowers customers to accelerate biomarker validation and improve lives.
Bio-Techne (NASDAQ: TECH) ha lanciato un menu ampliato di probi di ibiridazione in situ RNAscope™ per la ricerca sul trascrittoma umano e murino. Questa espansione mira a promuovere la ricerca sulla biologia spaziale e lo sviluppo di terapie e diagnostiche di nuova generazione. Il portafoglio di probe RNAscope a marchio Advanced Cell Diagnostics (ACD) include ora oltre 70.000 probe uniche in più di 450 specie. RNAscope è noto per la sua precisione spaziale, sensibilità e specificità, fornendo una visione a singola cellula della patologia delle malattie e della risposta terapeutica.
Questa espansione consente ai clienti di accelerare la validazione di nuovi biomarcatori RNA provenienti da genomica a singola cellula e programmi di scoperta spaziale. Disponibili su bio-techne.com, i clienti possono facilmente selezionare le probe RNAscope insieme agli anticorpi R&D Systems per studiare le variazioni nei fenotipi cellulari e negli stati funzionali. Le probe sono disponibili in formati manuali e automatizzati, inclusa la compatibilità con il sistema Lunaphore COMET™, consentendo un avanzamento senza soluzione di continuità dalla scoperta avanzata alla ricerca traslazionale o allo sviluppo di saggi clinici.
Il Dr. Matt McManus, Presidente del segmento Diagnostica e Biologia Spaziale di Bio-Techne, ha sottolineato che il portafoglio ampliato, con oltre 12.000 citazioni nella ricerca clinica e traslazionale, consente ai clienti di accelerare la validazione dei biomarcatori e migliorare la vita delle persone.
Bio-Techne (NASDAQ: TECH) ha lanzado un menú ampliado de probes de hibridación in situ RNAscope™ para la investigación del transcriptoma humano y de ratón. Esta expansión tiene como objetivo avanzar en la investigación de biología espacial y el desarrollo de terapias y diagnósticos de próxima generación. El portafolio de probes RNAscope de Advanced Cell Diagnostics (ACD) ahora incluye más de 70,000 probes únicas en más de 450 especies. RNAscope es conocido por su precisión espacial, sensibilidad y especificidad, proporcionando una vista a nivel de célula única de la patología de enfermedades y la respuesta terapéutica.
Esta expansión permite a los clientes acelerar la validación de nuevos biomarcadores de RNA provenientes de genómica de célula única y programas de descubrimiento espacial. Disponibles en bio-techne.com, los clientes pueden seleccionar fácilmente probes RNAscope junto con anticuerpos de R&D Systems para estudiar los cambios en los fenotipos celulares y estados funcionales. Las probes están disponibles en formatos manuales y automatizados, incluida la compatibilidad con el sistema Lunaphore COMET™, permitiendo un avance fluido desde el descubrimiento tardío hasta la investigación traslacional o el desarrollo de ensayos clínicos.
El Dr. Matt McManus, Presidente del segmento de Diagnósticos y Biología Espacial de Bio-Techne, enfatizó que el portafolio ampliado, con más de 12,000 citas en investigaciones clínicas y traslacionales, empodera a los clientes para acelerar la validación de biomarcadores y mejorar vidas.
Bio-Techne (NASDAQ: TECH)는 인간 및 쥐 전사체 연구를 위한 RNAscope™ 인사이트 하이브리다이제이션 프로브의 확장된 메뉴를 출시했습니다. 이 확장은 공간 생물학 연구와 차세대 치료제 및 진단 개발을 진전시키기 위한 것입니다. Advanced Cell Diagnostics (ACD) 브랜드 RNAscope 프로브 포트폴리오는 이제 450개 이상의 종에서 70,000개 이상의 고유 프로브를 포함합니다. RNAscope는 질병 병리학 및 치료 반응에 대한 단일 세포 관점을 제공하는 공간 정밀도, 민감도 및 특이성으로 주목받고 있습니다.
이 확장은 고객이 단일 세포 유전체학 및 공간 발견 프로그램에서 새로운 RNA 바이오마커의 검증을 가속화할 수 있도록 합니다. bio-techne.com에서 제공되며, 고객은 RNAscope 프로브를 선택하고 R&D Systems 항체와 함께 세포 표현형 및 기능적 상태의 변화를 연구할 수 있습니다. 프로브는 수동 및 자동 형식으로 제공되며, Lunaphore COMET™ 시스템과의 호환성이 포함되어 있어 늦은 발견에서 번역 연구 또는 임상 분석 개발로 원활하게 진행할 수 있습니다.
Bio-Techne의 진단 및 공간 생물학 부문 회장인 Dr. Matt McManus는 12,000건 이상의 임상 및 번역 연구 인용이 포함된 확장된 포트폴리오가 고객이 바이오마커 검증을 가속화하고 삶을 개선할 수 있도록 한다고 강조했습니다.
Bio-Techne (NASDAQ: TECH) a lancé un menu élargi de sondes d'hybridation in situ RNAscope™ pour la recherche sur le transcriptome humain et murin. Cette expansion vise à faire avancer la recherche en biologie spatiale ainsi que le développement de thérapies et de diagnostics de nouvelle génération. Le portefeuille de sondes RNAscope de Advanced Cell Diagnostics (ACD) comprend désormais plus de 70 000 sondes uniques dans plus de 450 espèces. RNAscope est reconnu pour sa précision spatiale, sa sensibilité et sa spécificité, offrant une vue à cellule unique de la pathologie des maladies et de la réponse thérapeutique.
Cette expansion permet aux clients d'accélérer la validation de nouveaux biomarqueurs d'ARN issus de la génomique unicellulaire et des programmes de découverte spatiale. Disponible sur bio-techne.com, les clients peuvent facilement sélectionner des sondes RNAscope ainsi que des anticorps R&D Systems pour étudier les changements dans les phénotypes cellulaires et les états fonctionnels. Les sondes sont disponibles en formats manuels et automatisés, y compris la compatibilité avec le système Lunaphore COMET™, permettant une transition fluide de la découverte tardive à la recherche translationnelle ou au développement de tests cliniques.
Le Dr Matt McManus, Président du segment Diagnostics et Biologie Spatiale de Bio-Techne, a souligné que le portefeuille élargi, avec plus de 12 000 citations dans la recherche clinique et translationnelle, permet aux clients d'accélérer la validation des biomarqueurs et d'améliorer la vie.
Bio-Techne (NASDAQ: TECH) hat ein erweitertes Menü von RNAscope™ In Situ Hybridisierungsproben für die Forschung zum menschlichen und murinen Transkriptom eingeführt. Diese Erweiterung zielt darauf ab, die Forschung zur räumlichen Biologie und die Entwicklung von Therapeutika und Diagnostika der nächsten Generation voranzutreiben. Das RNAscope-Probenportfolio der Advanced Cell Diagnostics (ACD) umfasst jetzt über 70.000 einzigartige Proben aus mehr als 450 Arten. RNAscope ist bekannt für seine räumliche Präzision, Sensitivität und Spezifität und bietet eine Einzelzellenansicht der Krankheitspathologie und der therapeutischen Reaktion.
Diese Erweiterung ermöglicht es den Kunden, die Validierung neuer RNA-Biomarker aus der Einzelzellgenomik und räumlichen Entdeckungsprogrammen zu beschleunigen. Auf bio-techne.com verfügbar, können Kunden RNAscope-Proben zusammen mit R&D Systems-Antikörpern auswählen, um Änderungen in Zellphänotypen und funktionalen Zuständen zu untersuchen. Die Proben sind in manuellen und automatisierten Formaten erhältlich, einschließlich der Kompatibilität mit dem Lunaphore COMET™-System, das einen nahtlosen Übergang von der späten Entdeckung zur translationale Forschung oder zur Entwicklung klinischer Assays ermöglicht.
Dr. Matt McManus, Präsident des Segments Diagnostik und räumliche Biologie von Bio-Techne, betonte, dass das erweiterte Portfolio mit über 12.000 Zitierungen in klinischer und translationaler Forschung es den Kunden ermöglicht, die Validierung von Biomarkern zu beschleunigen und das Leben zu verbessern.
- Launch of expanded RNAscope probe menu for human and mouse transcriptome.
- Over 70,000 unique probes across more than 450 species.
- Enables acceleration of new RNA biomarker validation.
- Available in manual and automated formats, including Lunaphore COMET™ system.
- Over 12,000 citations in clinical and translational research.
- None.
Insights
The significant expansion of Bio-Techne's RNAscope probe portfolio represents a strategic move to capitalize on the rapidly growing spatial biology market, currently valued at approximately
The commercial significance of this expansion is multifaceted:
- The extensive probe menu creates substantial recurring revenue opportunities through reagent sales and consumables
- Integration with R&D Systems antibodies enables cross-selling opportunities across Bio-Techne's product portfolio
- Compatibility with automated systems like Lunaphore COMET addresses the growing demand for high-throughput analysis in pharmaceutical research
- The impressive 12,000 citations in clinical and translational research demonstrate strong market validation and customer adoption
The expanded portfolio particularly strengthens Bio-Techne's position in the pharmaceutical and biotechnology research sectors, where demand for precise spatial biology tools is growing due to the rise of personalized medicine and complex therapeutic development. The RNAscope probe guarantee and ready-to-use formats reduce barriers to adoption while fostering customer loyalty and recurring purchases.
This strategic expansion enhances Bio-Techne's competitive moat in the spatial biology market, where first-mover advantages and technical expertise create significant barriers to entry. The company's ability to offer comprehensive solutions from discovery to clinical development positions it favorably against competitors and should drive sustained growth in the high-margin research tools segment.
Representing the most referenced spatial biology technology in the industry, RNAscope provides an unprecedented single-cell view of disease pathology and therapeutic response across a wide range of diseases.
Backed by the RNAscope probe guarantee, this new addition to the large and growing RNAscope probe menu enables customers to easily accelerate validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available for purchase on bio-techne.com, customers can easily select RNAscope probes together with R&D Systems antibodies to further illuminate changes in cell phenotypes and functional states. With ready-to-use manual and automated formats available for each RNAscope probe, including for use on the automated Lunaphore COMET™ system, researchers can seamlessly advance new RNA and multiomic biomarkers from late discovery to translational research or clinical assay development using the same RNAscope probe design.
"Empowering our customers with precise and scalable solutions to advance translational research and precision medicine is central to our mission," said Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "With over 12,000 citations in clinical and translational research combined, our expanded portfolio of gold-standard RNAscope probes enables customers to accelerate biomarker validation and ultimately improve lives."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-expanded-menu-of-rnascope-probes-for-human-and-mouse-transcriptome-to-advance-spatial-biology-302380023.html
SOURCE Bio-Techne Corporation
FAQ
What is the significance of Bio-Techne's expanded RNAscope probe menu?
How many unique RNAscope probes are included in Bio-Techne's expanded menu?
What are the benefits of Bio-Techne's RNAscope probes for researchers?
How can researchers purchase Bio-Techne's RNAscope probes?
What is the RNAscope probe guarantee?
What is the role of the Lunaphore COMET™ system in using RNAscope probes?
How many citations does Bio-Techne's RNAscope technology have in clinical and translational research?
